IDEXX Laboratories (IDXX) Morgan Stanley 24th Annual Global Healthcare Conference summary

Business performance and growth outlook

• Achieved strong Q2 results and raised full-year guidance, reflecting robust momentum and double-digit recurring revenue growth in reference labs and VetLab platforms.

• Reaffirmed long-term targets of 10%+ organic growth and 15%+ EPS growth, driven by innovation and utilization.

• Recurring revenue streams support high incremental gross margins and enable reinvestment in R&D and commercial expansion.

• Operating margin improvement is expected to continue, with a target of 50–100 basis points of annual expansion.

• International regions are experiencing strong double-digit growth as customer base broadens and diagnostic utilization expands.

Market trends and sector dynamics

• Despite modest headwinds in vet office visit growth, total pet population and medicalized pets have increased significantly since pre-pandemic.

• Demand for care is resilient across all economic cohorts, with aging pets and breed mix changes driving higher care intensity and diagnostic needs.

• Diagnostic utilization per visit continues to rise, with blood work inclusion growing by 50 basis points annually.

• Only about 20% of visits include blood work, highlighting significant opportunity for further penetration.

• Structural shift toward higher quality and intensity of care per visit is expected to be durable.

Innovation and product development

• Broad-based innovation cycle underway, with new platforms like inVue Dx and Cancer Dx addressing unmet needs and expanding diagnostic categories.

• inVue Dx launch has exceeded expectations, achieving $3,500–$5,500 recurring revenue per instrument, with significant headroom as FNA rolls out.

• FNA on inVue Dx enables real-time, high-quality diagnostics at 85% lower cost, doubling procedure volume for users.

• Cancer Dx offers multi-cancer detection at a disruptive $15 price point, driving new customer growth and blood work adoption.

• MultiQ Dx, a new diagnostic platform, will be unveiled at VMX in January, expected to be paradigm-changing and complementary to existing offerings.